Purity/Purification
99.66%
Molecular Formula
C14H23Cl2N3O
CAS No.
129830-38-2
Appearance
Solid
Solubility
DMSO: 199.8 mM
Water: 43.7 mM
(< 1 mg/ml refers to the product slightly soluble or insoluble)
Water: 43.7 mM
(< 1 mg/ml refers to the product slightly soluble or insoluble)
HNMR
Consistent with structure
HPLC
Consistent with structure
Conclusion
The test result is consistent with structure.
In vitro Activity
The inhibited potency of Y-27632 against the ROCK family is 100 times than other kinases including protein kinase C, cAMP-dependent kinase and myosin light chain kinase. Y-27632 prolongs the lag time and delays the appearance of BrdU-labeledcells in a concentration-dependent manner, delays of about 1 and 4 h are noticed in the Swiss 3T3 cells treated with 10 and 100uM Y-27632, respectively [1]. The application of a selective Rho-associated kinase (ROCK) inhibitor, Y-27632, to hES cellsmarkedly diminishes dissociation-induced apoptosis, increases cloning efficiency (from approximately 1% to approximately27%) and facilitates subcloning after gene transfer. Furthermore, dissociated hES cells treated with Y-27632 are protected fromapoptosis even in serum-free suspension (SFEB) culture and form floating aggregates [2]. Y-27632 promotes neuronaldifferentiation of adipose tissue-derived stem cells (ADSCs). Compared to 1.0 and 2.5 uM Y-27632 induced groups,percentages of neuronal-like cells achieved a peak in the 5.0 uM Y-27632 induced group [3]. Y-27632 selectively inhibitssmooth-muscle contraction by inhibiting Ca2+ sensitization. We identified the Y-27632 target as a Rho-associated proteinkinase, p160ROCK. Y-27632 consistently suppresses Rho-induced [4]
In vivo Activity
Y-27632 significantly decreased the blood pressure in a dose-dependent manner in spontaneously hypertensive rats: a fall of 50mm Hg was still observed 7 h after administration of 30 mg/kg of Y-27632. The same dose of this compound also caused asignificant and persistent fall in blood pressure in renal hypertensive rats, as well as in deoxycorticosterone acetate (DOCA)-salthypertensive rats. On the other hand, administration of the same dose of Y-27632 caused only a slight and transient fall in bloodpressure in control Wistar rats [4]. Y-27632 (5-10 mg/kg) and fasudil 5-25 (mg/kg) diminished onset of myoclonic jerks, clonicconvulsions and tonic hindlimb extensions in mice given pentylenetetrazole [5].
Kinase Assay
Recombinant ROCK1/2, PKN or citron kinase is expressed in Hela cells as Myc-tagged proteins by transfection using Lipofectamine and is precipitated from the ceillysates by the use of 9E10 monoclonal anti-Myc antibody coupled to G protein-Sepharose. Recovered immunocomplexes are incubated with various concentrations of [32P]ATP and 10 mg of histone type 2 as substrates in the absence or presence of various concentrations of either Y-27632 or Y-30141 at 30°C for 30 min in a total volume of 30 ul of the kinase buffer containing 50 mM HEPES-NaOH, pH 7.4, 10 mM MgCI2, 5 mM MnCI2, 0.02% Briji 35, and 2 mM dithiothreitol. PKCa is incubated with 5 uM [32P]ATP and 200 ug/ml histone type 2 as substrates in the absence or presence of various concentrations of either Y-27632 or Y-30141 at 30°C for 10 min in a kinase buffer containing 50 mM Tris-HCI, pH 7.5, 0.5 mM CaCl2, 5 mM magnesium acetate, 25 ug/ml phosphatidylserine, 50 ng/ml 12-0-tetradecanoyl phorbol-13-acetate and 0.001 % leupeptin in a total volume of 30 uL. Incubation is terminated by the addition of 10 uL of 43 laemmli sample buffer. After boiling for 5 min, the mixture is subjected to SDS-polyacrylamide gel electrophoresis on a 16% gel. The gel is stained with Coomassie Brilliant Blue and then dried. The bands corresponding to histone type 2 are excised, and the radioactivity is measured.
Cell Assay
Cell AssayHeLa cells are plated at a density of 3×10^4 cells per 3.5-cm dish. The cells are cultured in DMEM containing 10% FBS in thepresence of 10 mM Thymidine for 16 h. After the cells are washed with DMEM containing 10% FBS, they are cultured for anadditional 8 h, and then 40 ng/mL of Nocodazole is added. After 11.5 h of the Nocodazole treatment, various concentrations ofY-27632 (0-300 uM) or vehicle is added and the cells are incubated for another 30 min [1]
Animal Research
A group of animals was injected with a single dose of pentylenetetrazole (PTZ, 65?mg/kg) to investigate if the two Rho-kinase inhibitors, fasudil, and Y-27632, changed the onset of PTZ seizures. Fasudil, Y-27632 or saline was given intraperitoneally 30?min before the PTZ injection. Each mouse was then observed for a 15-min period to measure the onset of the first myoclonic jerk, the onset of the first clonic convulsion and the occurrence of tonic hindlimb extension. Some of the animals died after tonic hindlimb extension, which is an expected outcome of acute PTZ injection. After the observation period, all animals were killed by halothane anesthesia [5]. Seven-week-old male Wistar rats were anesthetized with sodium pentobarbital. A silver clip (0.2 mm in diameter) was placed on the left renal artery in the preparation of the renal hypertensive rats. In the preparation of the DOCA-salt hypertensive rats, the left kidney was removed and a DOCA pellet (50 mg) was implanted subcutaneously. The DOCA rats were then fed an 8% salt diet. Rats from both groups were used after 8 weeks in the experiments, together with a male, 17–22-week old spontaneously hypertensive rats. The average systolic pressure in these groups of hypertensive rats ranged from 209 to 237 mm Hg, and no significant difference was found between groups. Eight-week-old male Wistar rats were used as controls. Their average systolic pressure was 139 mm Hg. Y-27632was administered orally. The systolic blood pressure was measured by the tail cuff method at 1, 3, 5, 7 and 24 h. The rats were prewarmed to 40 8C for 10 min before each measurement. No toxicity was found in rats treated with 30 mg kg?1 of Y-27632 administered per os once per day for 10 days [4].
Preparation and Storage
0-4°C For short term (days to weeks), or -20°C for long term (months)
Related Product Information for Y-27632 2, inhibitor
Y-27632 is a selective inhibitor of ROCKs including p160ROCK (Ki: 140 nM) and ROCK2 (IC50: 800 nM).
Similar Products
Product Notes
The Y-27632 2 (Catalog #AAA14580) is an Inhibitor and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "Y-27632 2, Inhibitor" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.